Schering AG of Berlin and Avid Radiopharmaceuticals Inc. of Philadelphia are collaborating to develop diagnostic imaging agents for Alzheimer’s. The compounds, made by Avid, bind to amyloid plaques in the brain, which are thought to cause the disease. The compounds can be used with noninvasive imaging techniques such as PET. Under the agreement, Schering has the option to assume exclusive rights for the development and commercialization of such compounds for use with PET.